Alzamend Neuro Shares Lithium Imaging Data at Neuroscience 2026

Atlanta, Georgia, August 20, 2026

Phase 1/2A Study Examines Brain Network Changes

The accepted poster, titled “Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI,” will present neuroimaging findings from Alzamend’s randomized Phase 1/2A clinical trial of AL001. The presentation is scheduled for November 18 during the Neuropsychiatric Disorders session. The study evaluated healthy human participants receiving AL001 and conventional lithium carbonate using a randomized crossover design. Participants underwent two 14-day treatment periods separated by a 14-day washout, with advanced imaging and pharmacokinetic assessments conducted during the study. Researchers used 7T MRI and magnetic resonance spectroscopy (MRS) to investigate lithium distribution and treatment-associated effects within the brain. The specialized imaging methodology was developed by the laboratory of principal investigator Dr. Ovidiu C. Andronesi, Director of Multinuclear Magnetic Resonance Imaging at the Martinos Center for Biomedical Imaging and Associate Professor of Radiology at Harvard Medical School.

Advanced Neuroimaging Supports AL001 Development

The study incorporated a specialized engineered head coil designed to support high-resolution whole-brain lithium imaging. According to Alzamend, this approach enabled researchers to assess lithium concentrations in blood and individual brain structures while also examining brain chemistry, metabolism and biomarker effects. The company stated that the Phase 1/2A study confirmed that AL001 matches blood levels of standard lithium carbonate, while the imaging program provides additional information regarding how the investigational formulation interacts with the brain. Alzamend is developing AL001 as an ionic cocrystal formulation combining lithium with L-proline and salicylate, with the goal of improving brain delivery while potentially reducing systemic exposure. The company is investigating the candidate across several neurological and psychiatric conditions, including Alzheimer’s disease, bipolar disorder type 1, major depressive disorder and post-traumatic stress disorder. The newly accepted neuroimaging data are intended to provide another layer of evidence regarding AL001’s pharmacological effects and brain engagement.

Neuroscience 2026 Presentation Highlights Clinical Progress

The acceptance of the AL001 abstract provides Alzamend with an opportunity to share its Phase 1/2A findings with the international neuroscience research community. Neuroscience 2026, organized by the Society for Neuroscience, brings together researchers, clinicians and industry participants working across molecular, cellular, systems and clinical neuroscience. Alzamend said the presentation will focus specifically on changes in brain network connectivity following treatment with its novel lithium formulation. The company believes that advanced neuroimaging may help researchers better understand treatment-associated changes that cannot be assessed through conventional blood measurements alone. While lithium has been widely used in bipolar disorder for decades, Alzamend is pursuing AL001 as a differentiated formulation intended to address some limitations associated with conventional lithium therapy, including its narrow therapeutic window and systemic safety considerations. The company is also developing ALZN002, a cell-based therapeutic vaccine candidate targeting Alzheimer’s disease. The upcoming presentation represents a scientific dissemination milestone for AL001, although additional clinical research will be required to establish its safety, efficacy and potential therapeutic benefits across target diseases.

Source: Alzamend Neuro press relese